NRIX as reported
Nurix Therapeutics, Inc. reported $37M of revenue over the trailing twelve months, −58% on the year before. 8 reported series are charted on this page, each one as filed.
$37M
Revenue, trailing twelve months · to Q2 2026 · −58% against the twelve months before
- Net Income
- −$341M
Net Income · +65% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$305M
Free Cash Flow · +35% year on year · trailing twelve months to Q2 2026
- Op Margin
- −1073%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $37M | −58% | Q2 2026 |
| Net Income | −$341M | +65% | Q2 2026 |
| EPS | −$3.46 | +33% | Q2 2026 |
| Op Margin | −1073% | n/a | Q2 2026 |
| Net Margin | −1014% | n/a | Q2 2026 |
| ROE | −65% | n/a | Q2 2026 |
| ROA | −49% | n/a | Q2 2026 |
| Free Cash Flow | −$305M | +35% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Nurix Therapeutics, Inc. (NRIX) - Revenue & ProfitRevenue & ProfitNurix Therapeutics, Inc. (NRIX)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com